by Jennifer J Gao, Joyce Cheng, Erik Bloomquist, Jacquelyn
Sanchez, Suparna B Wedam, Harpreet Singh, Laleh Amiri-Kordestani, Amna Ibrahim,
Rajeshwari Sridhara, Kirsten B Goldberg, Marc R Theoret, Paul G Kluetz, Gideon
M Blumenthal, Richard Pazdur, Julia A Beaver, Tatiana M Prowell
Since the addition of CDKI to endocrine therapy seemed to
benefit all clinicopathological subgroups of interest in this pooled analysis,
further research is needed to identify patient subgroups for whom endocrine
therapy alone might be appropriate for first-line or second-line treatment of
hormone receptor-positive, HER2-negative metastatic breast cancer.
